New integration platform leverages a library of predefined connectors and allows clients to write their own custom connectors, easing the pain of creating and managing system integrations.
IRVINE, Calif.-June 14, 2006-DataLabs, an innovative developer of Internet-based software applications for clinical development, today announced the release of DataLabs Connect™ v2.0. DataLabs Connect is an enterprise-level middleware product built specifically for the biopharmaceutical industry. A first for the industry, DataLabs Connect includes an application server, management portal, connector framework and predefined connectors that integrate the entire suite of DataLabs' products including Galt Associates dsNavigator encoding and dictionary management product and other best-of-breed products.
DataLabs will be at booth #1829 at the DIA Annual Conference
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.